Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs

被引:80
|
作者
Rekhadevi, P. V. [1 ]
Sailaja, N. [1 ]
Chandrasekhar, M. [1 ]
Mahboob, M. [1 ]
Rahman, M. F. [1 ]
Grover, Paramjit [1 ]
机构
[1] Indian Inst Chem Technol, Div Biol, Toxicol Unit, Hyderabad 500007, Andhra Pradesh, India
关键词
D O I
10.1093/mutage/gem032
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Many anti-neoplastic drugs are used globally during chemotherapy in the treatment of cancer. However, occupational exposure to anti-cancer drugs can represent a potential health risk to humans. Investigations on the genotoxicity of these drugs are inconsistent. Further, information on the genotoxic potential of anti-neoplastic drugs in medical personnel from India is not available. Hence, the aim of this study was to carry out genotoxicity monitoring of nurses from the oncology department of a hospital in South India, occupationally exposed to anti-neoplastic drugs under routine working conditions. The level of genome damage was determined in whole blood with the comet assay as well as micronucleus test (MNT) and in buccal epithelial cells with MNT alone of 60 nurses handling anti-neoplastic drugs and 60 referents matched for age and sex. Urinary cyclophosphamide (CP), used as a marker for drug absorption, was also measured in the urine of the nurses. The DNA damage observed in the lymphocytes of exposed nurses was significantly higher than the controls. Similarly, a significant increase in micronuclei (MN) frequency with peripheral blood lymphocytes and buccal cells was observed in the exposed nurses compared to controls (P < 0.05). Multiple regression analysis showed that occupational exposure and age had a significant effect on mean comet tail length as well as on frequency of MN. The mean value of CP in urine of the nurses handling anti-neoplastic drugs was (mean +/- standard deviation; 0.44 +/- 0.26 mu g/ml). Our study has shown that increased genetic damage was evident in nurses due to occupational exposure to anti-neoplastics. This data corroborate the need to maintain safety measures to avoid exposure and the necessity of intervention in the case of exposure when using and handling anti-neoplastic drugs.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 50 条
  • [31] CARE OF THE PATIENT RECEIVING ANTI-NEOPLASTIC DRUGS
    WALTER, J
    NURSING CLINICS OF NORTH AMERICA, 1982, 17 (04) : 607 - 629
  • [32] ACTIVATION OF MACROPHAGE PROCOAGULANT EXPRESSION BY ANTI-NEOPLASTIC DRUGS
    WHEELER, HR
    GECZY, CL
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 281 - 281
  • [33] THE EFFECT OF ANTI-NEOPLASTIC DRUGS ON THE PHARMACOKINETICS OF ANTIPYRINE IN THE RAT
    HOYEMJOHANSEN, T
    SLORDAL, L
    HOYLANDSKJAER, A
    AARBAKKE, J
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1980, 47 (04): : 279 - 284
  • [34] Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential
    Maes, Ken
    Mondino, Anna
    Lasarte, Juan Jose
    Agirre, Xabier
    Vanderkerken, Karin
    Prosper, Felipe
    Breckpot, Karine
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [35] EXPOSURE OF PHARMACY PERSONNEL TO MUTAGENIC ANTI-NEOPLASTIC DRUGS
    NGUYEN, TV
    THEISS, JC
    MATNEY, TS
    ENVIRONMENTAL MUTAGENESIS, 1982, 4 (03): : 410 - 410
  • [36] THE COLLABORATIVE DEVELOPMENT OF A NEW FAMILY OF ANTI-NEOPLASTIC DRUGS
    CHENG, CC
    ZEECHENG, RKY
    NARAYANAN, VL
    ING, RB
    PAULL, KD
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1981, 2 (08) : 223 - 224
  • [37] RECOMMENDATIONS FOR THE SAFE HANDLING OF INJECTABLE ANTI-NEOPLASTIC DRUG PRODUCTS
    ZIMMERMAN, PF
    LARSEN, RK
    BARKLEY, EW
    GALLELLI, JF
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1981, 38 (11): : 1693 - 1695
  • [38] EXPOSURE OF PHARMACY PERSONNEL TO MUTAGENIC ANTI-NEOPLASTIC DRUGS
    NGUYEN, TV
    THEISS, JC
    MATNEY, TS
    CANCER RESEARCH, 1982, 42 (11) : 4792 - 4796
  • [39] PROCEDURES FOR HANDLING ANTI-NEOPLASTIC INJECTIONS IN COMPREHENSIVE CANCER CENTERS
    LEROY, ML
    ROBERTS, MJ
    THEISEN, JA
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1983, 40 (04): : 601 - 603
  • [40] ANTI-NEOPLASTIC DRUGS - CLINICAL PHARMACOLOGY AND THERAPEUTIC USE
    BENDER, RA
    ZWELLING, LA
    DOROSHOW, JH
    LOCKER, GY
    HANDE, KR
    MURINSON, DS
    COHEN, M
    MYERS, CE
    CHABNER, BA
    DRUGS, 1978, 16 (01) : 46 - 87